• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尽管在预防性乳房切除术标本中进行了彻底的术前 MRI 和超声评估,但仍发现隐匿性癌症的发生率很高:来自日本遗传性乳腺癌和卵巢癌登记处 2016 年的研究结果。

High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.

机构信息

Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.

The Japanese HBOC Consortium, Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.

出版信息

Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.

DOI:10.1007/s10549-018-4953-1
PMID:30203341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6245054/
Abstract

PURPOSE

Prophylactic surgery is a preemptive strategy for hereditary breast and ovarian cancer (HBOC). Prophylactic mastectomy (PM) reduces breast cancer risk by > 90%. The aim of our study is to analyze the information of the Japanese pedigrees and to utilize the results for clinical practice.

METHODS

We statistically analyzed records of HBOC registrees who had undergone BRCA1/2 genetic testing at seven medical institutions up until 2016. In the cases of PM, we examined breasts with the use of mammography (MMG), ultrasound (US), and magnetic resonance imaging (MRI) before surgery. After PM, the specimens were divided about 1 cm serially and examined in their entirety.

RESULTS

Of 1527 registrees who underwent BRCA testing, 1125 (73.7%) were negative for BRCA1/2 mutation, 297 (19.5%) were positive for BRCA1/2 mutation (BRCA1/2), and 105 (6.9%) had uncertain results. To decide whether to undergo total mastectomy vs. breast-conserving surgery (BCS), 370 registrees underwent presurgical genetic testing. During the follow-up period, four new-onset breast cancers were found among the 55 non-affected BRCA carriers. Among the 73 BRCA1/2 carriers who underwent BCS, 3 were found to have ipsilateral breast cancer. Of 189 BRCA1/2 carriers with unilateral breast cancer, 8 were found to have contralateral breast cancer. Of 53 PM specimens, 6 (11.3%) were found to have occult breast cancer despite using MMG, US, and MRI.

CONCLUSIONS

Our report showed a relatively higher incidence rate of occult cancer at 11.3% in PM specimens despite thorough pre-operative radiological evaluations, which included a breast MRI. Considering the occult cancer rates and the various pathological methods of our study and published studies, we propose the necessity of a histopathological protocol.

摘要

目的

预防性手术是遗传性乳腺癌和卵巢癌(HBOC)的一种先发制人的策略。预防性乳房切除术(PM)可将乳腺癌风险降低>90%。我们研究的目的是分析日本家系的信息,并将结果应用于临床实践。

方法

我们对截至 2016 年在七家医疗机构进行 BRCA1/2 基因检测的 HBOC 登记患者的记录进行了统计学分析。对于 PM,我们在手术前使用乳房 X 线照相术(MMG)、超声(US)和磁共振成像(MRI)检查乳房。PM 后,将标本每 1cm 切开并进行全面检查。

结果

在接受 BRCA 检测的 1527 名登记患者中,1125 名(73.7%)BRCA1/2 突变阴性,297 名(19.5%)BRCA1/2 突变阳性(BRCA1/2),105 名(6.9%)结果不确定。为了决定是否进行全乳房切除术与保乳手术(BCS),370 名登记患者进行了术前基因检测。在随访期间,在 55 名非受影响的 BRCA 携带者中发现了 4 例新发乳腺癌。在接受 BCS 的 73 名 BRCA1/2 携带者中,有 3 名发现同侧乳腺癌。在 189 名单侧乳腺癌的 BRCA1/2 携带者中,有 8 名发现对侧乳腺癌。在 53 个 PM 标本中,尽管使用了 MMG、US 和 MRI,但仍有 6 个(11.3%)发现隐匿性乳腺癌。

结论

尽管术前进行了包括乳房 MRI 在内的全面影像学评估,但我们的报告显示 PM 标本中隐匿性癌症的发生率相对较高,为 11.3%。考虑到隐匿性癌症的发生率以及我们研究和已发表研究的各种病理方法,我们提出了制定组织病理学方案的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/1bdccab2c4df/10549_2018_4953_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/e9fa5af0b599/10549_2018_4953_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/e7769e2e97e9/10549_2018_4953_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/1bdccab2c4df/10549_2018_4953_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/e9fa5af0b599/10549_2018_4953_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/e7769e2e97e9/10549_2018_4953_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c96/6245054/1bdccab2c4df/10549_2018_4953_Fig3_HTML.jpg

相似文献

1
High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.尽管在预防性乳房切除术标本中进行了彻底的术前 MRI 和超声评估,但仍发现隐匿性癌症的发生率很高:来自日本遗传性乳腺癌和卵巢癌登记处 2016 年的研究结果。
Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.
2
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术:外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
3
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.与BRCA1和BRCA2基因突变相关的遗传性乳腺癌卵巢癌综合征家族中女性接受预防性卵巢切除术后的腹腔内癌转移
Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039.
4
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?BRCA 突变携带者诊断为卵巢癌后患乳腺癌的风险:预防性乳房切除术是否必要?
Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
5
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.接受BRCA1和BRCA2检测的女性临床特征与风险降低干预措施之间的关联:一项单机构研究。
Cancer. 2006 Dec 15;107(12):2745-51. doi: 10.1002/cncr.22352.
6
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].[日本遗传性乳腺癌和卵巢癌的当前临床问题及近期趋势——HBOC的基因检测与降低风险手术]
Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9.
7
Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.日本遗传性乳腺癌和卵巢癌的遗传和临床特征:日本 HBOC 注册系统建立后的首次报告。
J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
8
Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.社区环境下遗传咨询后遗传性乳腺癌和卵巢癌高危女性的癌症预防和筛查实践。
Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.
9
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.BRCA1或BRCA2基因突变携带者的预防性卵巢切除术。
N Engl J Med. 2002 May 23;346(21):1616-22. doi: 10.1056/NEJMoa012158. Epub 2002 May 20.
10
Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.预防性手术在 BRCA1 或 BRCA2 基因突变携带者中的效果:一项荟萃分析和系统评价。
Clin Cancer Res. 2016 Aug 1;22(15):3971-81. doi: 10.1158/1078-0432.CCR-15-1465. Epub 2016 Mar 15.

引用本文的文献

1
Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.BRCA1/2致病变异携带者的临床病理特征及对侧乳腺癌风险:一项日本女性的多中心登记研究
Breast Cancer Res Treat. 2025 Sep 6. doi: 10.1007/s10549-025-07815-2.
2
The Incidence of Occult Malignancy in Contralateral Risk Reducing Mastectomy Among Affected Breast Cancer Gene Mutation Carriers in South Korea.韩国乳腺癌基因突变携带者对侧预防性乳房切除术中隐匿性恶性肿瘤的发生率
J Breast Cancer. 2025 Feb;28(1):1-10. doi: 10.4048/jbc.2024.0219.
3
Occult Breast Cancer in High-Risk Gene-Positive Pakistani Women Undergoing Contralateral Prophylactic Mastectomy/Prophylactic Mastectomy: Implications for Sentinel Lymph Node Biopsy.

本文引用的文献

1
Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.日本遗传性乳腺癌和卵巢癌的遗传和临床特征:日本 HBOC 注册系统建立后的首次报告。
J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
2
Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.应用双侧自动乳腺超声、磁共振成像和乳腺 X 线摄影对携带 BRCA1 或 BRCA2 突变的女性进行监测。
Radiology. 2017 Nov;285(2):376-388. doi: 10.1148/radiol.2017161218. Epub 2017 Jun 13.
3
接受对侧预防性乳房切除术/预防性乳房切除术的高危基因阳性巴基斯坦女性中的隐匿性乳腺癌:对前哨淋巴结活检的影响
Breast Cancer (Auckl). 2025 Jan 2;19:11782234241311018. doi: 10.1177/11782234241311018. eCollection 2025.
4
Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks.外科肿瘤学会乳腺疾病部位工作组关于双侧降低风险乳房切除术的声明:适应症、结果和风险
Ann Surg Oncol. 2025 Feb;32(2):899-911. doi: 10.1245/s10434-024-16484-2. Epub 2024 Nov 13.
5
The Novel Use of Magtrace in Chest Masculinizing Transgender Top Surgery.Magtrace在胸部男性化变性手术中的新用途。
Plast Reconstr Surg Glob Open. 2023 Dec 13;11(12):e5466. doi: 10.1097/GOX.0000000000005466. eCollection 2023 Dec.
6
A Look at the Other Side: High-Risk Lesions and Occult Contralateral Malignancy in Symmetry Procedures for Patients Undergoing Oncoplastic Breast-Conserving Surgery.对称性保乳手术中对侧隐匿性恶性肿瘤与高危病变
Ann Surg Oncol. 2023 Oct;30(10):6159-6166. doi: 10.1245/s10434-023-13894-6. Epub 2023 Aug 3.
7
Best treatment options for occult breast cancer: A meta-analysis.隐匿性乳腺癌的最佳治疗方案:一项荟萃分析。
Front Oncol. 2023 May 12;13:1051232. doi: 10.3389/fonc.2023.1051232. eCollection 2023.
8
Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review.BRCA 突变携带者的降低风险的乳腺和妇科手术:一篇叙述性综述。
J Clin Med. 2023 Feb 10;12(4):1422. doi: 10.3390/jcm12041422.
9
Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study.术前注射超顺磁氧化铁(SPIO)纳米颗粒诊断导管原位癌患者的延迟前哨淋巴结活检:SentiNot 研究。
Ann Surg Oncol. 2023 Jul;30(7):4064-4072. doi: 10.1245/s10434-022-13064-0. Epub 2023 Jan 31.
10
Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.携带BRCA1/2突变的乳腺癌患者对侧降低风险的局部治疗:系统评价与荟萃分析
Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.
Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial.
钼靶 X 线摄影和附加超声检查筛查乳腺癌的敏感性和特异性:日本策略性抗癌随机试验(J-START):一项随机对照试验。
Lancet. 2016 Jan 23;387(10016):341-348. doi: 10.1016/S0140-6736(15)00774-6. Epub 2015 Nov 5.
4
Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.家族性乳腺癌三联筛查试验强调了磁共振成像的重要性,并对乳腺X线摄影和超声检查的作用提出质疑,无论患者的突变状态、年龄和乳腺密度如何。
J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.
5
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.BRCA1/2 基因突变携带者的保乳手术:中期分析及文献综述
Ann Surg Oncol. 2015 Feb;22(2):370-6. doi: 10.1245/s10434-014-3883-3. Epub 2014 Jul 15.
6
Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.补充筛查超声可提高 BRCA1 和 BRCA2 基因突变携带者的癌症检出率。
Arch Gynecol Obstet. 2014 Mar;289(3):663-70. doi: 10.1007/s00404-013-3022-6. Epub 2013 Sep 18.
7
Sentinel lymph node biopsy for risk-reducing mastectomy.前哨淋巴结活检用于降低风险的乳房切除术。
Breast J. 2013 Sep-Oct;19(5):529-32. doi: 10.1111/tbj.12157. Epub 2013 Jul 19.
8
Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.BRCA1/2 相关乳腺癌患者行对侧乳房切除术可改善生存。
Breast Cancer Res Treat. 2013 Jul;140(1):135-42. doi: 10.1007/s10549-013-2583-1. Epub 2013 Jun 20.
9
Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.随着时间的推移,在一项高风险乳腺癌筛查研究中,MRI 对 DCIS 的检测率提高。
Breast J. 2011 Jan-Feb;17(1):9-17. doi: 10.1111/j.1524-4741.2010.01018.x.
10
Is breast cancer the same disease in Asian and Western countries?亚洲国家和西方国家的乳腺癌是同一种疾病吗?
World J Surg. 2010 Oct;34(10):2308-24. doi: 10.1007/s00268-010-0683-1.